Equity Research Analysis: DYNAVAX TECHNOLOGIES CORP (DVAX)
|Blank Capital Research Unit|Spot: $15.49
Price$15.49
Composite Score59.6/100
RatingHOLD (3★)
Rank#738 OF 7,333
Market Cap$1.2B
Intelligence Feed
Investing.comDec 25 Positive
Stock Market Today: Records, Metals Mania and Mixed Tech Tape
U.S. stock indices hover near record highs on Christmas Eve with the S&P 500 up 0.1% and year-to-date gains of 17.5%. Precious metals surge with gold breaking above $4,500/oz (up 70% YTD) and silver up 150%. The market shows mixed tech performance with AI leaders like Nvidia and Alphabet driving gains, while Intel faces pressure after Nvidia halts testing of its 18A process. Strong Q3 GDP growth of 4.3% and falling jobless claims support the bull case, though consumer confidence remains weak. The market is in late-cycle territory with valuations rich and stock selection critical.
The Motley FoolJan 30 Negative
Dynavax President and COO Sells 114,000 Shares on Sanofi Acquisition News
David Novack, President & COO of Dynavax Technologies, exercised and sold 114,000 shares for approximately $1.8 million on January 15, 2026, netting about $680,000 after costs. The sale comes following Dynavax's announcement of a $2.2 billion acquisition by French pharmaceutical giant Sanofi at $15.50 per share, representing a 40% premium to December closing prices.
yahooFeb 11 Positive
Sanofi Buyout Ends Dynavax Listing And Shifts Vaccine Upside To Group
Sanofi has completed its acquisition of Dynavax Technologies Corporation (NasdaqGS:DVAX), closing the transaction and changing the company’s ownership structure. Following the deal, Dynavax has been delisted from Nasdaq and removed from major stock indices, ending its status as a publicly traded company. The acquisition triggered broad changes to Dynavax’s board and executive leadership team, reshaping corporate governance. Dynavax, known for its work in vaccines and immunology, now sits...
finance.yahoo.comFeb 10 Neutral
Is It Time To Reassess Dynavax (DVAX) After The Agreed Sanofi Cash Acquisition Deal
If you are looking at Dynavax Technologies and wondering whether the current share price reflects its true worth, this article will walk you through what the numbers actually say about value. The stock closed at US$15.50 recently, with returns of 0.1% over 7 days, 0.6% over 30 days, 0.8% year to date, 22.0% over 1 year, 36.7% over 3 years and 58.5% over 5 years, which may have some investors reassessing both upside potential and risk. Recent news coverage around Dynavax has focused on its...
BenzingaJan 5 Neutral
$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Dynavax Technologies Corporation (NASDAQ: DVAX)
Monteverde & Associates PC, a securities class action firm, has announced an investigation into Dynavax Technologies Corporation's proposed acquisition by Sanofi. Under the deal terms, Dynavax shareholders are expected to receive $15.50 per share in cash. The firm is examining whether the transaction represents a fair deal for shareholders.